CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018 Providence News Team

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.

Enter content here

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

Most Recent Articles

Have a fun-filled, healthy summer with these suggestions.

Together, Oregon’s hospitals took home 19 awards in the nation’s premier recognition program for environmental performance in health care.

As a health care organization founded by incredibly strong women, Providence’s history is proudly steeped in the traditions of our foundresses, the sisters of St. Joseph and the sisters of Providence.

Growing the Providence Swedish comprehensive women’s health care program in the South Puget Sound, to bring the highest level of specialty services for women in our community.

Attend a FREE lecture at QVMC on June 29, 2023 at 6 p.m.

Hospital receives two national awards for commitment to best practices

Providence medical experts offer the most updated information about research and treatment options for breast and pancreatic cancer patients in two free virtual talks for patients and caregivers.

Attend a FREE live virtual lecture on spine care from our experts on June 22, 2023 at 5:30 p.m.

This marks the fourth time in five years that Providence Holy Cross is honored with this recognition.

Providence Little Company of Mary Medical Center Torrance (PLCMT) was recognized on Newsweek’s annual list of America’s Best Maternity Hospitals 2023.

New investigator-initiated trial at Providence to evaluate a triple combination of medications for treating melanoma, and two new studies evaluating medication combinations to treat AML.

Providence St. Joseph Hospital rated among best U.S. Maternity Hospitals on Newsweek’s 2023 List

Providence researchers awarded an R21 grant from the National Institutes of Health which provides funding for projects with potential to significantly advance biomedical research.

Clinical Decision Unit: New area helps meet community need

A free virtual online class hosted by Providence Cancer Institute will highlight what to eat during cancer treatments, how to manage side effects and how to speed healing.

Patrice Krant had arrhythmogenic right ventricular dysplasia. Her heart was failing, but thanks to Providence Heart Institute, she’s now feeling great a year after her life-saving surgery.

As a leader of a hospital that truly believes in a mission to safely care for the communities we serve, it’s difficult when any type of service can no longer be provided, especially when the patients